Show simple item record

dc.contributor.authorYALÇIN, KENDAL
dc.contributor.authorMueller, Tobias
dc.contributor.authorHaeussinger, Dieter
dc.contributor.authorLammert, Frank
dc.contributor.authorAKARCA, ULUS SALİH
dc.contributor.authorCakaloglu, Yilmaz
dc.contributor.authorGÜREL, SELİM
dc.contributor.authorWranke, Anika
dc.contributor.authorHardtke, Svenja
dc.contributor.authorHeidrich, Benjamin
dc.contributor.authorDalekos, George
dc.contributor.authorTabak, Fehmi
dc.contributor.authorYurdaydin, Cihan
dc.contributor.authorWedemeyer, Heiner
dc.contributor.authorCornberg, Markus
dc.contributor.authorİDİLMAN, RAMAZAN
dc.contributor.authorManns, Michael P.
dc.contributor.authorWoebse, Michael
dc.date.accessioned2021-03-02T17:33:15Z
dc.date.available2021-03-02T17:33:15Z
dc.identifier.citationWranke A., Hardtke S., Heidrich B., Dalekos G., YALÇIN K., Tabak F., GÜREL S., Cakaloglu Y., AKARCA U. S. , Lammert F., et al., "Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta", JOURNAL OF VIRAL HEPATITIS, 2020
dc.identifier.issn1352-0504
dc.identifier.othervv_1032021
dc.identifier.otherav_1965c2ba-1211-462f-a0c6-73818c2c01a9
dc.identifier.urihttp://hdl.handle.net/20.500.12627/4025
dc.identifier.urihttps://doi.org/10.1111/jvh.13366
dc.description.abstractHepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. PEG-interferon alpha-2a (PEG-IFN alpha-2a) is the only effective treatment but its long-term clinical impact is unclear. The aim of this study was to investigate the long-term outcome after 48 weeks of pegylated interferon alpha-2a therapy. We performed a retrospective follow-up study of the Hep-Net-International-Delta-Hepatitis-Intervention-Study 1 (HIDIT-I trial). Patients had received 48 weeks of treatment with either PEG-IFN alpha-2a plus adefovir dipivoxil (ADV) (Group I), PEG-IFN alpha-2a alone (Group II) or adefovir dipivoxil alone (Group III). Liver-related complications were defined as liver-related death, liver transplantation, liver cancer and hepatic decompensation defined as development of Child-Pugh scores B or C or an increase in Model for End-stage Liver Disease (MELD) scores of five or more points in relation to baseline values. Patients were considered for further analysis when they were retreated with PEG-IFN alpha-2a. Follow-up data (at least 1 visit beyond post-treatment week 24) were available for 60 patients [Group I, (n = 19), Group II (n = 20), Group III (n = 21)]. Mean time of follow-up was 8.9 (1.6 - 13.4) years. 19 patients were retreated with IFN-based therapy: 42% (n = 8) in PEG-IFN alpha-2a arms and 58% (n = 11) in the adefovir only arm. Clinical complications on long-term follow-up occurred in 17 patients and were associated with nonresponse to therapy and baseline cirrhosis. The annual event-free survival rate in patients with cirrhosis vs noncirrhotic patients at year 5 and 10 was 70% vs 91% and 35% vs 76%. Long-term follow-up of a large randomized clinical trial suggests that off-treatment HDV RNA response to PEG-IFN alpha-2a treatment leads to improved clinical long-term outcome.
dc.language.isoeng
dc.subjectTemel Tıp Bilimleri
dc.subjectİmmünoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectVİROLOJİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectYaşam Bilimleri
dc.subjectGastroenteroloji-(Hepatoloji)
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectViroloji
dc.subjectMikrobiyoloji ve Klinik Mikrobiyoloji
dc.subjectGASTROENTEROLOJİ VE HEPATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectBULAŞICI HASTALIKLAR
dc.titleTen-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta
dc.typeMakale
dc.relation.journalJOURNAL OF VIRAL HEPATITIS
dc.contributor.departmentHannover Medical School , ,
dc.contributor.firstauthorID2285766


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record